×
About 1,218 results

ALLMedicine™ Anaplastic Astrocytoma Center

Research & Reviews  370 results

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
https://clinicaltrials.gov/ct2/show/NCT04197934

Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of EGFR/EGFRvIII inhibitor WSD0922-FU (WSD0922-FU) in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, ...

Low-Grade Astrocytoma
http://emedicine.medscape.com/article/1156429-overview

Aug 4th, 2022 - Background Low-grade astrocytomas are a heterogeneous group of intrinsic central nervous system (CNS) neoplasms that share certain similarities in their clinical presentation, radiologic appearance, prognosis, and treatment. The most common intrin...

Low-Grade Astrocytoma
https://emedicine.medscape.com/article/1156429-print

Aug 4th, 2022 - Background Low-grade astrocytomas are a heterogeneous group of intrinsic central nervous system (CNS) neoplasms that share certain similarities in their clinical presentation, radiologic appearance, prognosis, and treatment. The most common intrin...

Low-Grade Astrocytoma
https://emedicine.medscape.com/article/1156429-overview

Aug 4th, 2022 - Background Low-grade astrocytomas are a heterogeneous group of intrinsic central nervous system (CNS) neoplasms that share certain similarities in their clinical presentation, radiologic appearance, prognosis, and treatment. The most common intrin...

Temozolomide Chronotherapy for High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02781792

Aug 3rd, 2022 - Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone. Give its activity in astrocytomas, TMZ is commonly used in grade III anaplas...

see more →

Drugs  16 results see all →

Clinicaltrials.gov  87 results

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
https://clinicaltrials.gov/ct2/show/NCT04197934

Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of EGFR/EGFRvIII inhibitor WSD0922-FU (WSD0922-FU) in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, ...

Temozolomide Chronotherapy for High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02781792

Aug 3rd, 2022 - Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone. Give its activity in astrocytomas, TMZ is commonly used in grade III anaplas...

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04047303

Jul 8th, 2022 - CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive o...

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT03528642

Jun 30th, 2022 - PRIMARY OBJECTIVE: I. Determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of telaglenastat (CB-839) hydrochloride (HCl) when combined with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagn...

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT02644291

Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...

see more →

News  14 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Brain Tumors Exact Higher Mortality Toll in Men Than Women
https://www.medscape.com/viewarticle/968594

Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...

Toca 511 Shows Promise in High-Grade Glioma
https://www.onclive.com/view/toca-511-shows-promise-in-highgrade-glioma

Dec 20th, 2020 - Timothy Cloughesy, MD The gene for an anticancer drug was successfully transduced in high-grade gliomas, according to data from a phase I trial of Toca 511 presented at the 2016 Society for Neuro-Oncology Annual Meeting. Additionally, the median ...

New Era of CDK Targeting Gets Rolling in Oncology
https://www.onclive.com/view/new-era-of-cdk-targeting-gets-rolling-in-oncology

Dec 5th, 2020 - In the oncology sphere, 2 members of the cyclin-dependent kinase (CDK) family have long stood out from the crowd. Serving as gatekeepers at the entry to the cell cycle, CDK4 and CDK6 make ideal therapeutic targets to block the unchecked proliferat...

Oncolytic Virus Therapy Passes Early Efficacy Tests in Glioma Subtypes
https://www.onclive.com/view/oncolytic-virus-therapy-passes-early-efficacy-tests-in-glioma-subtypes

Dec 5th, 2020 - Clark C. Chen, MD, PhD A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), in early clinical studies, according t...

see more →